NetworkNewsBreaks – Biogen Inc. (NASDAQ: BIIB) Featured in Mizuho Securities Research Report
Biogen (NASDAQ: BIIB) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Housekeeping: (1) Revenues came in line, but would have slightly missed if you back out the $40MM benefit of inventory in Spinraza ROW, and (2) there was a slight bump to EPS guidance for the year on reduced R&D. Note, Rituxan and Tecfidera erosion is occurring faster than expected. . . . Aducanumab: Language largely unchanged -- still in the guide. The slides discuss 600 clinical sites in the US that will be able to treat "shortly after potential approval".…







